0001402328 false 0001402328 2022-02-18 2022-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares




Form 8-K


Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):

February 18, 2022



(Exact name of small business issuer as specified in its charter)


Colorado 000-52898 20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number) (IRS Employer ID No.)


6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R0A5

(Address of principal executive offices)


(514) 426-6161

(Issuer’s Telephone Number)


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol Name of Each Exchange on Which Registered


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 


Emerging growth company 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 1.01. Entry into a Material Definitive Agreement.


On February 18, 2022, Sunshine Biopharma, Inc. (the “Company”) entered into a research agreement with the Arizona Board of Regents on behalf of the University of Arizona (the “University”). Pursuant to the research agreement, the University agreed to use reasonable efforts to perform a research project focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2, in consideration for certain milestone payments to be made by the Company. Under the agreement, the University granted the Company a first option to negotiate for a commercial, royalty-bearing license for all intellectual property invented or authored by University personnel under the research project. The agreement will expire upon completion of the work specified therein, subject to the right of either party to terminate the agreement upon 90 days’ written notice, or the right of the Company to terminate the agreement upon 30 days’ written notice if the Company determines that the research results do not favorably support the development of a commercially viable drug.


The foregoing description of the research agreement is qualified by reference to the full text of the agreement which is filed as an exhibit to this report.


Item 8.01. Other Events.


In connection with the closing of the Company’s public offering, and consistent with the disclosure therein, on February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock held by the Company’s chief executive officer, Dr. Steve N. Slilaty, for a redemption price equal to the stated value of $0.10 per share.


On February 25, 2022, the Company issued a press release regarding the research agreement. A copy of the press release is attached as Exhibit 99.1 hereto.


Item 9.01 Financial Statements and Exhibits


(b) Exhibits. The following exhibits are included in this report:


No. Description
10.1 Research Agreement, dated February 18, 2022, between the Company and the University
99.1 Press Release
104 Cover Page Interactive Data File (formatted in iXBRL)









Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: February 25, 2022 SUNSHINE BIOPHARMA, INC.
  By: /s/ Dr. Steve N. Slilaty                          
  Dr. Steve N. Slilaty, Chief Executive Officer




















Exhibit 10.1


Research Agreement



This Research Agreement (the “Agreement”) is effective on the date of the last authorized signature below (the "Effective Date"), between Sunshine Biopharma, Inc. (“Sponsor”), with offices located at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, H9R 0A5, Canada, and the Arizona Board of Regents on behalf of the University of Arizona, an Arizona body corporate ("University"), with offices located at University Services Building Room 510, 888 N. Euclid Ave., Tucson, Arizona 85719.


If checked, this Agreement is also subject to additional terms and conditions set forth in the attached Exhibit C. In the event of a conflict between any specific terms or conditions in this Agreement and Exhibit C, Exhibit C shall govern.



The parties hereby agree as follows:


1.Scope of Work and Payment


1.1Research Project. The University will use reasonable efforts to perform the research project as described in the Statement of Work (the “SOW”) incorporated herein by reference as “Exhibit A: Research Project Statement of Work dated November 15, 2021” (the “Research Project”), in consideration for Sponsor making the payments in accordance with the milestones (the “Milestones”) specified in the SOW as described in Exhibit B (the “Costs of Research”). Unless otherwise set forth on Exhibit B, payments will be due within 30 days of the date of the University’s invoice. The Research Project will be supervised by Gregory Thatcher, Ph.D., employed by University (the “Principal Investigator”).


1.2Reports. During the Term of this Agreement, the University shall provide the Sponsor with brief bi-weekly email reports outlining the work performed to date, the results obtained and planned next steps (the “Reports”). Such Reports shall be used by the University and Sponsor to make decisions in respect of the Milestones and make adjustments to the SOW, if necessary. A final report shall be in the form of manuscript for a publication to be co-authored by University and Sponsor scientists and prepared by the University within sixty (60) days following completion of the Research Project (the “Final Report”).


1.3Non-Exclusivity of Research. Both parties acknowledge and agree that each party may engage in other research that is similar to the Research Project but not involving the same compounds of the Research Project, funded by public or private sources and conducted separately, and the other party has no rights or obligations with respect to such separate research.


1.4Equipment and Supplies. Equipment and supplies purchased specifically to conduct the Research Project belong to University at the termination of this Agreement.


2.Term and Termination


2.1Term. This Agreement begins on the Effective Date and will expire upon completion of the work specified in the SOW and delivery of the Final Report to Sponsor(the “Term”), unless sooner terminated in accordance with the provisions of this Section 2.


2.2Termination for Convenience. Either party may terminate this Agreement at any time upon ninety (90) days written notice to the other party. Sponsor may terminate this Agreement at any time upon thirty (30) days written notice to the University if it determines that the research results do not favorably support the development of a commercially viable drug based on the science of the Research Project.







2.3Termination for Breach. Either party may terminate this Agreement in the event the other party commits a material breach of any of the terms or conditions of this Agreement, and fails to remedy such breach within thirty (30) days after receipt of written notice from the other party. The right to terminate for material breach is in addition to any other remedies which a party may have at law or in equity.2.4 Effect of Termination. Upon any expiration or termination of this Agreement, University will work to close down the Research Project, including termination of any obligations in force (except those that are non-cancelable), and will notify Sponsor of those obligations remaining as of the date of termination. Sponsor will pay University all Costs of Research incurred by University up to the date of termination. Further, if Sponsor terminates for its convenience or if University terminates for Sponsor’s material breach, Sponsor will reimburse University for all costs associated with termination. Termination or expiration of this Agreement will not affect the rights and obligations of the parties that have accrued prior to the termination date, including non-cancellable commitments, and specifically the obligations set forth in Sections headed Confidentiality Obligations, Indemnification and Limitation of Liability and General Provisions will survive termination or expiration. If Sponsor terminates this Agreement prior to completion of the Research Project or if University terminates for material breach by Sponsor, the Intellectual Property rights set forth in the Section headed Intellectual Property will terminate; otherwise these rights will survive expiration of the Agreement.


3.Research Results


Sponsor and University agree that, in exchange for paying the Costs of Research, Sponsor may use the results of the research (“Research Results”) for any purpose, but may not publish Research Results prior to Principal Investigator’s publication of Research Results. The University retains ownership of the Research Results, and the right to publish as set forth in Section 5. Any Research Result that also constitutes Intellectual Property as set forth in Section 4.1 below is considered Intellectual Property, and is subject to the terms set forth in Section 4 below.


4.Intellectual Property


4.1Ownership of Intellectual Property. The parties acknowledge that inventions, discoveries, and other technology that is patentable, or that is copyrightable software (“Intellectual Property”) may arise from the Research Project. University owns all Intellectual Property invented or authored by University personnel under the Research Project (“University Intellectual Property”). The parties will jointly own all Intellectual Property invented or authored jointly by University personnel and Sponsor personnel under the Research Project (“Joint Intellectual Property”). Inventorship and authorship will be determined in accordance with United States intellectual property laws. This Agreement does not grant either party any rights to any pre-existing Intellectual Property or to any Intellectual Property developed outside the scope of the Research Project.


4.2Disclosure and Filing. All Intellectual Property arising from University’s performance of the Research Project will be disclosed to University’s tech transfer organization, Tech Launch Arizona, who will promptly provide Sponsor with a confidential written disclosure of the Intellectual Property. The University may file for patent or other protection for University Intellectual Property at its discretion, or at the request of the Sponsor. Sponsor will reimburse University for fees and expenses associated with patent prosecution or other protection if such actions are taken at Sponsor request, or if Sponsor seeks a license under Section 4.3. University will control patent prosecution on any University Intellectual Property. If Sponsor is reimbursing University, the parties will collaborate during the patent prosecution process, and the University will consider all of Sponsor’s input in good faith.


4.3License to Intellectual Property. The University grants to Sponsor a non-exclusive right to use the University Intellectual Property for internal research purposes. The University also grants to Sponsor the first option to negotiate for a commercial, royalty-bearing license .under University Intellectual Property and University’s rights in Joint Intellectual Property within the field of use and territory to be mutually agreed by the parties. Sponsor may exercise this option by submitting a request in writing to University, and the parties will negotiate such license arrangement in good faith and on commercially reasonable terms. The option must be exercised in writing within three (3) months after completion of the Research Project and delivery of final report to Sponsor as specified in Section 2.1 (“Option Period”). If Sponsor fails to exercise the option within the Option Period, or if the parties do not reasonably agree on terms for a license within three (3) months after the date the Sponsor exercises the option, the University will have no further obligation to Sponsor with respect to a commercial license to that Intellectual Property.







4.4Retained Rights. Without limiting any other rights it may have and even if Sponsor exercises its option as set forth in Section 4.3 above, the University specifically reserves the right in and to the University Intellectual Property and Joint Intellectual Property for any research, public service, and/or educational purposes, and to grant licenses to other academic institutions for these same reserved rights.




Notwithstanding anything to the contrary in this Agreement, the University and its employees have the right, at their discretion, to release information or to publish any data, writings, or material resulting from the Research Project, including Research Results and Intellectual Property, and to use it in any way for its educational and research purposes.  The University will furnish the Sponsor with a copy of any proposed publication in advance of the proposed publication date and grant the Sponsor thirty (30) days for review and comment. Within this period, the Sponsor may request the University, in writing, to delay such publication for a maximum of an additional (60) days in order to protect the potential patentability of any invention described therein. Such delay will not, however, be imposed on the filing of any student thesis or dissertation. Sponsor’s failure to object to a publication or presentation within the thirty (30) day period above will be deemed acceptance by Sponsor.


6.Public Statements; Use of Names and Logos


6.1No Use of Names or Logos. Neither party is permitted to use the names, logos, or other identifiers associated with the other party without such party’s express prior written consent in each instance.


6.2Press Releases. Except as required by law, neither party will issue any press release or other public statements in connection with this Agreement or the Research Project without the other party’s prior written consent. University will acknowledge Sponsor’s support of the Research Project in scientific publications and communications. All statements by the parties will accurately describe the scope and nature of their participation. University may, without prior consent from Sponsor, list Research Project title, amount awarded, Sponsor name, and Principal Investigator(s) names and department(s) affiliation(s) in its reports, which while not disseminated, are available to the public.


6.3No University Endorsements. In no event shall Sponsor (or its successors, employees, agents or contractors) state or imply in any publication, advertisement, or other medium that the University approved or endorsed any product or service. In no event shall the University’s performance of the Research Project be considered the basis for any endorsement of a product or service.


7.Indemnification, Limitation of Liability, Limitation of Remedies, and Insurance


7.1Indemnification by Sponsor. Sponsor will indemnify, defend and hold harmless Principal Investigator and University, its governing board, officers, agents, and employees, from any liability, loss or damage they may suffer as the result of claims, demands, costs or judgments against them arising out of either party’s performance of the Research Project pursuant to this Agreement, and/or Sponsor’s use of the University Intellectual Property, Joint Intellectual Property, Research Results, or other information or materials provided under this Agreement, provided, however, that any such liability, loss, or damage resulting from the following are excluded from this agreement to indemnify and hold harmless: (a) University’s failure to adhere to the terms of the Research Project Statement of Work in all material respects; (b) University’s failure to comply with any applicable law or regulation; or (c) negligence or willful misconduct in the performance of this Agreement by the Principal Investigator, University, or its board, officers, agents, or employees as determined by a court of law. Principal Investigator and University agree to notify Sponsor promptly of any such claim or action, and to cooperate with and to authorize Sponsor to carry out the sole management and defense of such claim or action. Sponsor will not compromise or settle any claim or action without the prior written approval of each of the following if they are a named party: Principal Investigator, University, its governing board, officers, agents, or employees.











7.4Insurance. At all times during the Term, Sponsor shall obtain and keep in full force and effect, general and professional liability insurance, including coverage for death, bodily or personal injury, and property damage, including products liability, with limits of not less than $3,000,000 per each occurrence and $5,000,000 in the aggregate.


8.General Provisions


8.1Applicable Law and Venue. This Agreement will be interpreted pursuant to the laws of the State of Arizona, where the Research Project is performed. Any arbitration or litigation between the parties will be conducted in Pima County, Arizona, and Sponsor hereby submits to venue and jurisdiction in Pima County, Arizona. This Agreement may be subject to mandatory non-binding arbitration in accordance with applicable law.


8.2Non-Discrimination. The parties agree to be bound by state and federal laws and regulations governing equal opportunity and non-discrimination and immigration.


8.3Conflict of Interest. This Agreement is subject to the provisions of A.R.S. 38-511. Within three years from the Effective Date, the University may cancel this Agreement if any person significantly involved in negotiating, drafting, securing or obtaining this Agreement for or on behalf of the University becomes an employee in any capacity of Sponsor or a consultant to Sponsor with reference to the subject matter of this Agreement while the Agreement or any extension thereof is in effect.


8.4Notices. Notices will be in writing and deemed effective when sent, postage prepaid to:


If to Sponsor:


Sunshine Biopharma Inc.

6500 Trans-Canada Highway, 4th Floor

Pointe-Claire, Quebec H9R 0A5



If to University (Notices and Correspondence):

UAHS Contracts

1670 E. Drachman Street, 9th Floor

P.O. Box 210216

Tucson, Arizona 85721







8.5Entire Agreement; Modifications. This Agreement embodies the entire understanding of the parties and supersedes any other agreement or understanding between the parties relating to the subject matter hereof. There are no additional or supplemental agreements related to the subject matter hereof. No waiver, amendment or modification of this Agreement will be valid or binding unless written and signed by the parties. Waiver by either party of any breach or default of any clause of this Agreement by the other party will not operate as a waiver of any previous or future default or breach of the same or different clause of this Agreement. In the event Sponsor issues a purchase order or instrument concerning the subject of this Agreement, the parties expressly agree that the terms and conditions in such purchase order or instrument will have no force or effect.


8.6Export Laws. The parties acknowledge that this Agreement is subject to compliance with applicable United States laws, regulations, or orders including those that may relate to the export of technical data and equipment, such as International Traffic in Arms Regulations (“ITAR“) and/or Export Administration Act/Regulations (“EAR”), as may be amended, and agree to comply with all such laws, regulations or orders. It is the intent of the parties not to disclose any export-controlled information. However, if a party determines that export-controlled information must be disclosed, such party will provide the other party with written notice containing the nature of the export-controlled information prior to any exchange of export-controlled information. Sponsor is solely responsible for any violation of such laws and regulations involving Sponsor or its affiliates, and will defend, indemnify and hold harmless the University if any legal action of any nature results from any such violation.


8.7Assignment. This Agreement may not be assigned or transferred (either directly or indirectly, by operation of law or otherwise, including by way of a merger, acquisition or other sale event) without the prior written consent of the other party, which consent will not be unreasonably withheld. This Agreement is binding upon and will inure to each party's respective permitted successors in interest.


8.8Severability. If any provision of this Agreement is held void or unenforceable, the remaining provisions will nevertheless be effective, the intent being to effectuate this Agreement to the fullest extent possible.


8.9Independent Contractors. The parties are deemed independent contractors and may not bind the other, except as provided for herein or authorized in writing by the other party.


9.10Force Majeure. If either party hereto shall be delayed or hindered in, or prevented from, the performance of any act required hereunder for any reason beyond such party’s direct control, including but not limited to, strike, lockouts, labor troubles, governmental or judicial actions or orders, riots, insurrections, war, acts of God, inclement weather, epidemics, pandemics, or other reason beyond the party’s control (a “Disability”) then such party’s performance shall be excused for the period of the Disability. Any timelines affected by a Disability shall be extended for a period equal to the delay and any affected Budget shall be adjusted to account for cost increases or decreases resulting from the Disability.


9.11Public Records. When fully executed, this Agreement itself cannot be Confidential Information per the Arizona Public Records Law, Arizona Revised Statutes 39-121 and 41-1350


9.10Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute one and the same document, and is binding on all Parties notwithstanding that each of the Parties may have signed different counterparts. Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered original signature unless prohibited by applicable law.



(signatures next page)







IN WITNESS THEREOF, the parties execute this Agreement as of the day and year written below.


SPONSOR   The Arizona Board of Regents
    on behalf of The University of Arizona
By: /s/ Steve N. Slilaty                                By: /s/ Elisha Johnson, JD                                
Name: Steve N. Slilaty, Ph.D.                     Name: Elisha Johnson, JD
Title: CEO                                                      Title: Director, Clinical Trials and Contracting
Date: 2/2/22                                                   Date: 2/18/22                                                       
    Read and Acknowledged
    /s/ Gregory Thatcher, PhD




















Research Project -- Statement of Work


Dated November 15, 2021

For reference only











































Payment Schedule and Cost




































Exhibit C

Additional Binding Terms

If checked, the following terms apply to the Agreement:








































Exhibit 99.1




For Immediate Release

February 25, 2022




Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into an agreement with the University of Arizona for the purposes of advancing the development of novel PLpro inhibitors discovered by University of Arizona and University of Illinois Chicago researchers. The development of the Company’s lead PLpro inhibitor, SBFM-PL4, is currently continuing at the University of Georgia. At the University of Arizona, the research effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties of 3 university owned PLpro inhibitors followed by efficacy testing in MA10 mice infected with SARS-CoV-2. Molecules showing efficacy in infected mice will be advanced to human trials.


“We are delighted to be working with the University of Arizona Coronavirus research team led by Dr. Gregory Thatcher as well as the commercialization team at Tech Launch Arizona,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “It is of paramount importance to find a wide array of inhibitors for PLpro, as this virus encoded protease is responsible for suppression of the human immune system thereby enabling the virus to cause severe illness,” he added.


About the University of Arizona


The University of Arizona, a land-grant university with two independently accredited medical schools, is one of the nation's top 50 public universities, according to U.S. News & World Report. Established in 1885, the university is widely recognized as a student-centric university and has been designated as a Hispanic Serving Institution by the U.S. Department of Education. The university ranked in the top 20 in 2019 in research expenditures among all public universities, according to the National Science Foundation, and is a leading Research 1 institution with $734 million in annual research expenditures. The university advances the frontiers of interdisciplinary scholarship and entrepreneurial partnerships as a member of the Association of American Universities, the 66 leading public and private research universities in the U.S. It benefits the state with an estimated economic impact of $4.1 billion annually.


About Tech Launch Arizona


Tech Launch Arizona is the office of the University of Arizona that creates social and economic impact through commercializing inventions stemming from university research. The office builds connections between talented UA faculty, researchers and staff and experienced entrepreneurs and investors, to create an ecosystem that refines ideas that start in research and innovation and grows them into products and businesses that benefit society. TLA supports entrepreneurship through a variety of initiatives, including training startup teams in customer discovery, providing funding to advance early-stage inventions toward market readiness, and hosting challenges to help students and faculty move innovative ideas from concept to societal impact. In FY2021, TLA took in 274 invention disclosures, had 100 U.S. patents issued, and executed 124 licenses and options for UArizona technologies. The university has launched more than 100 startups since the office was founded in 2012.







About Sunshine Biopharma


In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements


This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.


For Additional Information:


Camille Sebaaly, CFO

Direct Line: 514-814-0464